Thoracic Cancer最新文献

{"title":"Synchronous Surgical Therapy for Bilateral Multiple Pulmonary Nodules: A Single-Center Analysis of 108 Cases.","authors":"Huayu He, Jie Bai, Jizheng Tang, Yingze Ning, Wei He, Chutong Lin, Shanwu Ma, Tong Wang, Jingdi Wang, Jintao Song, Keyi Wang, Lili Zheng, Guangliang Qiang","doi":"10.1111/1759-7714.70320","DOIUrl":"10.1111/1759-7714.70320","url":null,"abstract":"<p><strong>Background: </strong>With the widespread use of low-dose computed tomography (LDCT), the detection rate of bilateral multiple pulmonary nodules (BMPNs) has increased significantly. Surgical treatment remains the main treatment for multiple pulmonary nodules (MPNs), and its therapeutic value for simultaneous BMPNs is becoming increasingly prominent. However, the safety and feasibility of synchronous bilateral surgery (SBS) remain underexplored. This study aimed to evaluate the perioperative outcomes and prognosis of patients who underwent SBS for multiple pulmonary nodules.</p><p><strong>Methods: </strong>We retrospectively analyzed the data from 108 patients who underwent synchronous bilateral resection for MPNs at Peking University Third Hospital between January 2015 and December 2025. Clinical, pathological, and perioperative data were collected. Postoperative complications were classified using the Clavien-Dindo system. Risk factors for postoperative complications were identified using a logistic regression analysis. Overall survival was estimated using the Kaplan-Meier method.</p><p><strong>Results: </strong>Among the 108 patients, 62.0% were female, and 79.6% were nonsmokers. The most common surgical combination was wedge resection combined with wedge resection (44.4%). The mean postoperative hospital stay was 6.55 ± 3.03 days. The most common complications were constipation (53.7%) and sleep disorders (51.9%), while severe complications occurred in fewer than 5% of the patients. No 30-day mortality or unplanned secondary surgery was observed. Prolonged chest tube drainage (> 3 days) was identified as an independent risk factor for grade ≥ 2 complications (p < 0.05). The 5-year overall survival rate was 92.3%.</p><p><strong>Conclusions: </strong>SBS for MPNs is safe and feasible in selected patients, with acceptable perioperative outcomes and favorable survival.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"17 11","pages":"e70320"},"PeriodicalIF":2.6,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13250759/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148212562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Relationship Between Pulmonary Spiculation and Central Fibrosis, Along With Other Clinicopathological Features, in Invasive Lung Adenocarcinoma and Its Prognostic Significance.","authors":"Hanbo Le, Yongkui Zhang, Heping Wang, Yuanyuan Wen, Liyong Qian, Hui He","doi":"10.1111/1759-7714.70319","DOIUrl":"10.1111/1759-7714.70319","url":null,"abstract":"<p><strong>Background: </strong>Spiculation is a critical radiological feature in invasive adenocarcinoma (IAC). This study explores its pathological association with central fibrosis subtypes to refine prognostic evaluation.</p><p><strong>Materials and methods: </strong>A total of 327 cases of IAC were divided into spiculated (n = 158) and non-spiculated (n = 169) groups. Associations between spiculation, central fibrosis, intratumoral fibrosis, and other factors were analyzed. Multivariate logistic regression was used to identify contributors to spiculation formation. Survival was assessed using Kaplan-Meier curves and Cox regression. Propensity score matching (PSM) was utilized to minimize confounding variables.</p><p><strong>Results: </strong>The spiculated group showed higher rates of pleural indentation, central fibrosis > 5 mm, and increased intratumoral fibrosis, collagen content in both the original and matched cohorts (all p < 0.05), while spiculation was associated with elastin content in the original cohort (p = 0.020), this correlation disappeared after PSM. Multivariate logistic regression identified central fibrosis, collagen content, pleural indentation, tumor size, and lymph node metastasis as independent predictors of spiculation. Spiculation was associated with poorer survival in the original cohort (p < 0.001), but this significance disappeared after PSM (p = 0.860). In Cox analysis, spiculation was not an independent prognostic factor. Alveolar collapse > 5 mm was an independent protective factor, while intratumoral fibrosis and lymph node metastasis were adverse prognostic factors.</p><p><strong>Conclusion: </strong>Spiculation is closely associated with central fibrosis. It shows a stronger correlation with collagen content than with elastin content. While reflecting underlying aggressiveness, spiculation lacks independent prognostic value. Integrating spiculation with central fibrosis is essential for precise risk stratification.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"17 11","pages":"e70319"},"PeriodicalIF":2.6,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13238589/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148164779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-Line Alectinib Versus Ceritinib With or Without Brain Radiotherapy in ALK-Positive Non-Small Cell Lung Cancer with Brain Metastases: A Real-World Multicenter Study from Vietnam.","authors":"Hoang Gia Nguyen, Xuan Hau Nguyen, Phuong Nguyen, Thu Huong Nguyen, Quang Bui Vinh","doi":"10.1111/1759-7714.70325","DOIUrl":"10.1111/1759-7714.70325","url":null,"abstract":"<p><strong>Background: </strong>This study compared the efficacy of first-line alectinib versus ceritinib and evaluated the role of upfront brain radiotherapy (RT) in patients with ALK-positive non-small cell lung cancer (NSCLC) and brain metastases (BM).</p><p><strong>Methods: </strong>We retrospectively analyzed 108 patients with ALK-positive NSCLC and baseline BM treated with first-line alectinib (n = 42) or ceritinib (n = 66) at two Vietnamese centers between 2019 and 2025. Intracranial and systemic responses were assessed by RANO-BM and RECIST v1.1 criteria, respectively. Survival outcomes were analyzed using the Kaplan-Meier method and multivariable Cox regression.</p><p><strong>Results: </strong>First-line alectinib demonstrated superior intracranial disease control compared with ceritinib (iDCR 97.6% vs. 83.3%, p = 0.026; median iPFS 40.4 vs. 17.2 months, univariable HR 0.46, 95% CI 0.26-0.82, p = 0.005). Systemic PFS was also significantly longer with alectinib (35.9 vs. 11.5 months, univariable HR 0.38, 95% CI 0.22-0.65, p = 0.001). Exploratory subgroup analyses suggested differential effects of upfront brain RT by TKI, but interaction tests were non-significant (p = 0.642 for iPFS, p = 0.837 for systemic PFS). In multivariable analysis, alectinib remained an independent predictor of better iPFS (HR 0.38, 95% CI 0.20-0.70, p = 0.002) and systemic PFS (HR 0.34, 95% CI 0.20-0.59, p = 0.001). Grade ≥ 3 adverse events occurred in 19.0% of patients with alectinib versus 34.8% with ceritinib (p = 0.068).</p><p><strong>Conclusions: </strong>In this real-world Vietnamese cohort, first-line alectinib showed superior intracranial and systemic efficacy over ceritinib. In resource-limited settings, ceritinib combined with upfront brain RT is a reasonable clinical alternative. The differential benefit of brain RT between the two TKIs remains hypothesis-generating.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"17 12","pages":"e70325"},"PeriodicalIF":2.6,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13277389/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148273240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revisiting Thoracic Duct Resection in Esophageal Squamous Cell Carcinoma: A Propensity-Matched Analysis and Immunologic Insight Into Recurrence Risk.","authors":"Xin Zhang, Xin-Yu Liu, Yu-Jin Lv, Shi-Ning Li, Yong Ao, Le-Qi Zhong, Yi Hu","doi":"10.1111/1759-7714.70309","DOIUrl":"10.1111/1759-7714.70309","url":null,"abstract":"<p><strong>Background: </strong>Esophageal squamous cell carcinoma (ESCC) is an aggressive malignancy with a poor prognosis. In an effort to reduce recurrence, the thoracic duct (TD), a key conduit for immune and nutritional homeostasis, is sometimes resected during esophagectomy. The clinical and immunological impact of this procedure remains controversial. This study therefore aimed to evaluate the prognostic significance of intraoperative thoracic duct resection (TDR) in ESCC patients.</p><p><strong>Methods: </strong>We retrospectively analyzed 722 patients with ESCC who underwent McKeown esophagectomy at Sun Yat-sen University Cancer Center between January 2020 and December 2022. Patients were classified into TDR and TD-preserved groups. Propensity score matching (PSM) was used to balance baseline characteristics. Overall survival (OS) and recurrence-free survival (RFS) were compared using Kaplan-Meier analysis and Cox regression models.</p><p><strong>Results: </strong>After PSM, there were no significant differences between the TDR and TD-preserved groups in median OS (both 33.96 months) or in 1-, 3-, and 5-year OS rates (p = 0.66). RFS was also similar (p = 0.31). Subgroup analyses showed that TDR had no significant impact on OS or RFS, regardless of adjuvant therapy or immunotherapy at recurrence. However, among patients without lymph node metastasis (pN0), TDR was associated with a higher recurrence risk (HR, 2.09; 95% CI, 1.16-3.73; p = 0.013).</p><p><strong>Conclusions: </strong>Intraoperative TDR did not improve long-term survival in ESCC and may increase recurrence risk in early-stage node-negative patients. Routine TDR should be avoided, and its indication individualized.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"17 11","pages":"e70309"},"PeriodicalIF":2.6,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13240132/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148043888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and Imaging Characteristics in the Diagnosis and Surgical Management of Nipple Discharge Without Clinically Palpable Masses: A Retrospective Cohort Study.","authors":"Yang Yang, Ting Lin, Jiaxuan Li, Houpu Yang, Fei Xie, Siyuan Wang, Dingbao Chen, Shu Wang, Lei Chen, Miao Liu","doi":"10.1111/1759-7714.70332","DOIUrl":"10.1111/1759-7714.70332","url":null,"abstract":"<p><strong>Background: </strong>The study aimed to investigate clinical and imaging features in the diagnosis and surgical management of nipple discharge without palpable masses.</p><p><strong>Methods: </strong>Consecutive patients undergoing surgery for nipple discharge without palpable masses (January 2014-December 2024) were retrospectively enrolled. Clinical, imaging (ultrasound, mammography, MRI), surgical, and pathological data were analyzed. Diagnostic performance of imaging modalities for intraductal lesions/malignancy and their role in incision selection were evaluated. Multivariate regression identified independent risk factors.</p><p><strong>Results: </strong>Among 664 patients (676 breasts), 512 were pathology-positive cases. Older age (> 50 years), postmenopausal status, bloody/yellow discharge, and single-duct involvement correlated with intraductal-lesions/malignancy (p < 0.05). MRI demonstrated superior sensitivity for detecting intraductal-lesions (81.25%) and cancer (87.32%) versus ultrasound (64.51%/74.26%) and mammography (26.46%/50.39%), with 84.62% concordance in surgical localization. Bloody/yellow discharge, positive ultrasound, and MRI independently predicted intraductal-lesions (p < 0.05).</p><p><strong>Conclusion: </strong>MRI offers optimal diagnostic sensitivity and precise spatial guidance for surgery. Bloody/yellow discharge, along with positive ultrasound and MRI findings, informs risk stratification and surgical intervention.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"17 12","pages":"e70332"},"PeriodicalIF":2.6,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13291552/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148309693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surgical Invasiveness Trumps Chronological Age: Determinants of Short-Term Recovery in Octogenarian Lung Cancer Patients.","authors":"Qixuan Wang, Yuan Xu, Hongsheng Liu, Yingzhi Qin, Zhewei Zhao, Dongjie Ma","doi":"10.1111/1759-7714.70287","DOIUrl":"10.1111/1759-7714.70287","url":null,"abstract":"<p><strong>Objective: </strong>To characterize perioperative outcomes and quantify the relative contribution of patient-related versus procedure-related factors to short-term recovery (LOS and CTD) in octogenarians undergoing minimally invasive lung resection within an ERAS pathway.</p><p><strong>Methods: </strong>We reviewed 106 consecutive patients aged 80 years or older with suspected primary NSCLC who underwent video-assisted or robotic-assisted resection (2020-2025) under standardized ERAS care. Primary outcomes were LOS and CTD. Determinants were assessed with multivariable linear models of log(LOS + 1) and log(CTD + 1) among malignant survivors (n = 99).</p><p><strong>Results: </strong>Median age was 81 years (IQR 80-83); 57.5% were men. Procedures included wedge resection (52.8%), segmentectomy (9.4%), and lobectomy (37.7%); 96.2% were VATS and 3.8% RATS. Median LOS was 4.0 days (IQR 3.0-5.8) and CTD 3.0 days (IQR 1.0-4.0). Complications occurred in 13.2%, and perioperative mortality was 0.9%. Sublobar resection (vs. lobectomy) was independently associated with shorter LOS (standardized beta -0.262, p = 0.011) and CTD (standardized beta -0.326, p = 0.001). Age was not associated with LOS, but showed a small inverse association with CTD (standardized beta -0.219, p = 0.018). No patient was readmitted within 30 days, chest tube reinsertion occurred in 1 patient (0.9%), and 10 patients (9.4%) were transferred to lower-level hospitals after discharge.</p><p><strong>Conclusions: </strong>In carefully selected octogenarians managed with minimally invasive surgery and ERAS, surgical invasiveness (extent of resection) was the dominant modifiable driver of recovery, whereas chronological age alone provided limited incremental discrimination of recovery speed. Favorable in-hospital recovery was not associated with increased short-term adverse events after discharge.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"17 11","pages":"e70287"},"PeriodicalIF":2.6,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13239877/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148043868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Utility of Comprehensive Genomic Profiling for Advanced Non-Small Cell Lung Cancer: A Single-Center Retrospective Study.","authors":"Shuji Murakami, Yukihiko Hiroshima, Seigo Katakura, Tetsuro Kondo, Terufumi Kato, Tomoyuki Yokose, Haruhiro Saito","doi":"10.1111/1759-7714.70304","DOIUrl":"10.1111/1759-7714.70304","url":null,"abstract":"<p><strong>Background: </strong>For advanced non-small cell lung cancer (NSCLC), biomarker testing using multiplex companion diagnostics has become the standard of care. However, challenges remain in detecting rare mutations and resistance mechanisms after targeted therapy. We evaluated the prevalence of druggable genetic aberrations and the clinical utility of comprehensive genomic profiling (CGP) performed after completion of standard treatment in real-world practice.</p><p><strong>Methods: </strong>This retrospective study analyzed 108 patients with advanced or recurrent non-small cell lung cancer who underwent comprehensive genomic profiling testing between January 2019 and December 2023 at the Kanagawa Cancer Center Hospital, Japan. Profiling was conducted using the OncoGuide NCC Oncopanel System, FoundationOne, and FoundationOne Liquid companion diagnostics.</p><p><strong>Results: </strong>Druggable genetic aberrations were detected in 37% of the patients, with epidermal growth factor receptor mutations being the most common. Resistance mechanisms were identified in 9 of 19 patients who underwent re-biopsy after targeted therapy. Non-smokers had a significantly higher rate of druggable mutations (55.6%) than did smokers (27.8%). Treatment based on comprehensive genomic profiling findings was recommended for 35.2% of the patients; however, only 16.6% received the suggested therapy. In a landmark survival analysis, patients who received genomically matched therapy demonstrated a trend toward prolonged overall survival compared with those who did not (log-rank p = 0.054).</p><p><strong>Conclusions: </strong>CGP testing can identify actionable mutations missed by conventional diagnostics and may provide additional therapeutic opportunities in NSCLC.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"17 11","pages":"e70304"},"PeriodicalIF":2.6,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13240551/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148144849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prospective Multicenter Observational Study of Anlotinib in Advanced Non-Small Cell Lung Cancer: Real-World Evidence From China.","authors":"Jinlin Wang, Youhong Dong, Fengjun Cao, Ruizhi Ran, Yifa Yin, Yinping Li, Yang Fu, Yanhua Xu, Li Kuang, Guiming Chen, Guangqiao Qu, Jun Li, Zhiguo Luo, Qibin Song, Yuan Chen, Xinhua Xu, Tienan Yi, Qian Chu","doi":"10.1111/1759-7714.70306","DOIUrl":"10.1111/1759-7714.70306","url":null,"abstract":"<p><strong>Background: </strong>Anlotinib has shown remarkable efficacy in later-line treatment of advanced non-small cell lung cancer (NSCLC). This prospective real-world study evaluated its efficacy and safety in routine clinical practice.</p><p><strong>Methods: </strong>Patients from 13 centers in China received anlotinib (8-12 mg) once daily on days 1-14 of a 21-day cycle until disease progression, death, or unacceptable toxicity. Primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety.</p><p><strong>Results: </strong>From July 2019 to October 2021, 352 of 373 enrolled patients received ≥ 2 cycles of anlotinib. Median follow-up was 35.5 months. Median PFS and OS were 5.8 months (95% CI, 5.0-6.4) and 11.3 months (95% CI, 9.9-13.1), respectively. ORR and DCR were 19.3% and 84.4%. Multivariable analysis indicated that age ≥ 70 years was independently associated with poorer OS, though a clinically meaningful benefit remained (PFS, 5.9 months; OS, 9.6 months). Efficacy appeared generally similar regardless of baseline brain metastases. Median PFS and OS were 6.3 and 12.7 months in the second-line setting, and 5.5 and 11.3 months in the≥ third-line setting. Treatment-related adverse events occurred in 10.5%, with grade ≥ 3 events in 1.4%; no treatment-related deaths were observed.</p><p><strong>Conclusion: </strong>In this real-world cohort, anlotinib demonstrated effectiveness and acceptable tolerability in advanced NSCLC. Given the observational design, exploratory analyses-including age, treatment line, and baseline brain metastases-should be interpreted with caution. These findings complement limited existing real-world data and may inform future clinical research and decision-making.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov identifier: NCT04871997.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"17 11","pages":"e70306"},"PeriodicalIF":2.6,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13238780/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148164694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RETRACTION: FLOT1 promotes tumor development, induces epithelial-mesenchymal transition, and modulates the cell cycle by regulating the Erk/Akt signaling pathway in lung adenocarcinoma.","authors":"","doi":"10.1111/1759-7714.70326","DOIUrl":"10.1111/1759-7714.70326","url":null,"abstract":"<p><strong>Retraction: </strong>L. Zhang, Y. Mao, Q. Mao, W. Fan, L. Xu, Y. Chen, L. Xu and J. Wang, \"FLOT1 promotes tumor development, induces epithelial-mesenchymal transition, and modulates the cell cycle by regulating the Erk/Akt signaling pathway in lung adenocarcinoma,\" Thoracic Cancer 10, no. 4 (2019): 909-917, https://doi.org/10.1111/1759-7714.13027. The above article, published online on 05 March 2019 in Wiley Online Library (wileyonlinelibrary.com), and its correction, (https://doi.org/10.1111/1759-7714.14990), has been retracted by agreement between the journal Editor-in-Chief, Tateaki Naito; and John Wiley & Sons Australia, Ltd. The retraction has been agreed upon following concerns raised by a third party. An investigation identified duplication between the OEFLOT1_NC flow cytometry plot presented in Figure 2f of this article and a plot published previously by a different author group. The authors were contacted for comment and supporting data, but did not respond. In light of these findings, the editors consider the results and conclusions to be unreliable. The authors did not respond to our notice of retraction.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"17 12","pages":"e70326"},"PeriodicalIF":2.6,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13275200/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148273230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Factors Associated With Non-Completion of Durvalumab Maintenance Therapy After Chemoradiotherapy in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Single-Center Retrospective Study.","authors":"Masaaki Kotake, Satoshi Watanabe, Yuki Sakai, Toshiaki Kikuchi, Akira Toyama","doi":"10.1111/1759-7714.70329","DOIUrl":"10.1111/1759-7714.70329","url":null,"abstract":"<p><strong>Background: </strong>Durvalumab maintenance following concurrent chemoradiotherapy (CCRT) is the standard treatment for unresectable stage III non-small cell lung cancer (NSCLC); however, some patients discontinue treatment before completing 12 months. We explored whether pretreatment peripheral blood inflammatory and nutritional markers are associated with durvalumab non-completion.</p><p><strong>Methods: </strong>We retrospectively reviewed patients with locally advanced NSCLC who initiated durvalumab between August 2018 and April 2024. Laboratory data obtained within 7 days before the first dose were analyzed. Completion was defined as 12 months (365 days) of treatment. Routine laboratory parameters and inflammatory/nutritional indices were compared between completers and non-completers. Exploratory multivariable logistic regression and clinically adjusted sensitivity analyses were performed.</p><p><strong>Results: </strong>Eighty patients were included: 36 completers and 44 non-completers. Durvalumab was discontinued because of disease progression (n = 24), radiation pneumonitis (n = 14), immune-related adverse events (n = 5), and aspiration pneumonia (n = 1). Conventional inflammatory indices did not differ between groups. In the primary exploratory multivariable model, a higher albumin-to-globulin (A/G) ratio was associated with durvalumab completion (OR, 9.74; 95% CI, 1.01-93.9; p = 0.048), whereas RDW-SD showed a non-significant inverse association with completion (OR, 0.942; 95% CI, 0.883-1.01; p = 0.076). After adjustment for age, ECOG performance status, and histology, these associations were not statistically significant.</p><p><strong>Conclusions: </strong>Lower A/G ratio and higher RDW-SD before durvalumab initiation may be associated with non-completion. Given the exploratory design, limited sample size, attenuation after clinical adjustment, and heterogeneous reasons for discontinuation, these findings require external validation.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"17 12","pages":"e70329"},"PeriodicalIF":2.6,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13279546/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148279018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}